What to Expect When Taking Mounjaro: A Week-by-Week Reality Check

What the trial data says about the early weeks

The SURMOUNT-1 results, published in the New England Journal of Medicine, involved 2,539 adults with obesity who were randomised to tirzepatide or placebo for 72 weeks. Weight loss was not linear. The steepest rate of change typically occurred in the middle phase of treatment, once participants had titrated to a therapeutic dose, not at the outset. This matters because many people starting Mounjaro expect an immediate shift on the scales and feel discouraged when the 2.5mg first pen delivers modest early results. That starter dose exists to reduce the risk of nausea, not to produce substantial weight loss; its job is tolerability. If you want a fuller picture of the journey ahead, our guide to what to expect on Mounjaro walks through the experience from the first injection onward. You can read more about what the first few weeks feel like physically on our guide to starting Mounjaro.

The NHS tirzepatide patient page notes that the medicine works by mimicking two gut hormones (GIP and GLP-1) to reduce appetite and slow gastric emptying. This dual mechanism is why tirzepatide is the only medicine of its kind licensed in the UK for weight management. The practical effect is that food becomes less appealing and smaller portions feel more satisfying, but this shift in hunger signals builds over weeks rather than arriving overnight.

Side effects: what tends to happen and when it settles

Gastrointestinal effects are the most commonly reported experience across the SURMOUNT programme. Nausea sits at the top of the list, followed by loose stools, constipation, indigestion and burping. For most people these are mild to moderate and cluster around two moments: the very start of treatment, and the days immediately after each dose step-up. By the second week on a given dose, many people find the effects have largely settled, which is why the standard titration moves in four-week blocks rather than faster.

Fatigue, mild headache and dizziness appear less often but are worth knowing about. Injection-site reactions are usually minor and short-lived; rotating between the abdomen, thigh and upper arm helps. If you experience severe, persistent stomach pain that radiates to your back, seek medical help promptly, this can be a sign of pancreatitis, which the MHRA flagged as an infrequent but serious risk in its January 2026 Drug Safety Update for GLP-1 medicines. You should always report any suspected side effects at the MHRA's Yellow Card scheme. Detailed side-effect information specific to tirzepatide is also covered in our tirzepatide patient experience overview.

Weight loss: realistic timelines and what influences progress

Expecting to see meaningful movement on the scales within the first month is reasonable only if your expectations are calibrated to a moderate early loss. Most people taking Mounjaro notice appetite changes within weeks one to four; actual weight reduction then compounds as doses increase. The pattern described in SURMOUNT-1 suggests the greatest rate of loss occurred between the third and sixth months, by which time many participants were on higher doses. By 72 weeks, the average reduction at 15mg was around 20–21% of starting body weight, with some analyses reporting higher figures in specific subgroups.

What you eat alongside the medicine matters. Mounjaro does not override diet entirely, it changes the signals, and you still determine the content of your plate. Protein adequacy and staying well hydrated become more important as appetite drops, partly because smaller eating windows make it easier to undereat both. A useful habit: spend thirty seconds before your weekly injection reviewing what you ate and drank over the week. It takes under a minute, and the pattern across four weeks tells you far more than a single weigh-in. For a broader picture of the treatment landscape, the weight-loss treatment overview sets Mounjaro alongside the other licensed options.

If you have questions about how quickly the medicine begins to act, our explainer on Mounjaro's timescale covers the evidence in more detail. And if you want to understand how week two typically differs from week one, the week-two guide is worth a read before your second injection.

The clinical structure behind your experience

Mounjaro is a prescription-only medicine. Everything about how the experience unfolds (which dose you start on, how quickly you increase, whether you continue) is determined by a prescriber, not by a schedule you set yourself. NICE's appraisal of tirzepatide, TA1026, recommends review if less than 5% weight loss is achieved after six months at the highest tolerated dose, which is why the clinical check-ins alongside treatment are not optional extras.

At nume, a GPhC-registered Independent Prescriber reads your consultation, a real clinician, before any medicine is dispensed. That same clinical review applies to every repeat order; there is no automatic renewal. The Mounjaro overview page covers licensing, eligibility and the full NICE criteria. If you are ready to see whether you qualify, you can check your eligibility with a free consultation. Our clinical team oversees every patient journey, and common questions are answered if you want to explore further before getting started.